Talus Bio tacks on $11M to target hard-to-reach transcription factors

Seattle-based Talus Bioscience has raised $11.2 million in an early fundraising round, money that will go toward advancing the biotech’s portfolio of preclinical cancer programs and help build out the biotech’s drug discovery platform.